Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC

NCT07231575 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Neoadjuvant Immunotherapy
NSCLC
Chemo-free Therapy

Interventions

RADIATION: SBRT
DRUG: Immunotherapy
DRUG: antiangiogenesis therapy

Sponsor

Sun Yat-sen University